Original article (Clinical research)

Clinical analysis of adverse reactions of ankylosing spondylitis patients treated by different TNF-inhibitors

  • ZHOU Lan-lan ,
  • DING Yu
Expand
  • Department of Rheumatology, the First Affiliated Hospital, Nanjing Medical University, Nanjing 210029, China

Online published: 2014-01-02

Abstract

Objective To study immunologic mechanisms induced by different TNF-inhibitors in ankylosing spondylitis treatment. Methods A total of 180 patients with ankylosing spondylitis received TNF-α inhibitors were collected. Distribution of different TNF-inhibitors and adverse reactions of patients were observed. Results Three kinds of TNF-inhibitors were used. Among the patients, 50 were treated with Infliximab; 50, with Adalimumab; and 80, with Etanercept. The adverse reaction rates were 14%, 13%, 4%, and 6% in Infliximab, Etanercept (domestic), Etanercept (imported), and Adalimumab, respectively. The humanized TNF-inhibitor was safer than the human-mouse chimeric TNF-inhibitor. Conclusion The human-mouse chimeric TNF-inhibitor was more likely to induce adverse reactions, which might be related to its immunogenicity.

Cite this article

ZHOU Lan-lan , DING Yu . Clinical analysis of adverse reactions of ankylosing spondylitis patients treated by different TNF-inhibitors[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2013 , 33(12) : 1620 . DOI: 10.3969/j.issn.1674-8115.2013.12.014

Outlines

/